Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1093/intimm/dxy079

http://scihub22266oqcxt.onion/10.1093/intimm/dxy079
suck pdf from google scholar
30508092!6440441!30508092
unlimited free pdf from europmc30508092    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=30508092&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid30508092      Int+Immunol 2019 ; 31 (4): 187-198
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects #MMPMID30508092
  • Uehara T; Eikawa S; Nishida M; Kunisada Y; Yoshida A; Fujiwara T; Kunisada T; Ozaki T; Udono H
  • Int Immunol 2019[Mar]; 31 (4): 187-198 PMID30508092show ga
  • CD11b+ myeloid subpopulations, including myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), play crucial roles in the suppression of T-cell-mediated anti-tumor immunity. Regulation of these cell types is a primary goal for achieving efficient cancer immunotherapy. We found that metformin (Met) induces CD11b+-cell-mediated growth inhibition of a K7M2neo osteosarcoma independent of T cells, as growth inhibition of K7M2neo was still observed in wild-type (WT) mice depleted of T cells by antibodies and in SCID; this contrasted with the effect of Met on Meth A fibrosarcoma, which was entirely T-cell-dependent. Moreover, the inhibitory effect seen in SCID was abrogated by anti-CD11b antibody injection. PMN-MDSCs were significantly reduced in both spleens and tumors following Met treatment. In TAMs, production of IL-12 and TNF-alpha, but not IL-10, became apparent, and elevation of MHC class II with reduction of CD206 was observed, indicating a shift from an M2- to M1-like phenotype via Met administration. Metabolically, Met treatment decreased basal respiration and the oxygen consumption rate (OCR)/extracellular acidification rate (ECAR) ratio of CD11b+ cells in tumors, but not in the spleen. In addition, decreased reactive oxygen species (ROS) production and proton leakage in MDSCs and TAMs were consistently observed in tumors. Uptake of both 2-deoxy-2-d-glucose (2-NBDG) and BODIPY(R) decreased in MDSCs, but only BODIPY(R) incorporation was decreased in TAMs. Overall, our results suggest that Met redirects the metabolism of CD11b+ cells to lower oxidative phosphorylation (OXPHOS) while elevating glycolysis, thereby pushing the microenvironment to a state that inhibits the growth of certain tumors.
  • |Animals[MESH]
  • |CD11b Antigen/metabolism[MESH]
  • |Cell Differentiation[MESH]
  • |Cell Line, Tumor[MESH]
  • |Cellular Reprogramming[MESH]
  • |Cytokines/metabolism[MESH]
  • |Humans[MESH]
  • |Immunity[MESH]
  • |Macrophages/*immunology[MESH]
  • |Metformin/*metabolism[MESH]
  • |Mice[MESH]
  • |Mice, Inbred BALB C[MESH]
  • |Mice, SCID[MESH]
  • |Myeloid Cells/*immunology[MESH]
  • |Myeloid-Derived Suppressor Cells/*immunology[MESH]
  • |Osteosarcoma/*immunology[MESH]
  • |Oxidative Phosphorylation[MESH]
  • |Th1 Cells/immunology[MESH]
  • |Th2 Cells/immunology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box